Skip to content
SHARP episode artwork

Dec 10, 2014 5 min

SHARP

from Translational and Clinical

Lowering cholesterol in chronic kidney disease The Study of Heart and Renal Protection (SHARP) concluded that around a quarter of all heart attacks, strokes, and operations to open blocked arteries could be avoided in people with chronic kidney disease by using the combination of ezetimibe and simvastatin to lower blood cholesterol levels. The SHARP study involved almost 9,500 volunteers aged 40 or over with chronic kidney disease recruited from 380 hospitals in 18 countries. Volunteers were randomly allocated to take either cholesterol-lowering therapy with a tablet containing ezetimibe 10mg daily and simvastatin 20mg daily, or matching dummy "placebo" tablets for an average of 5 years.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

SHARP

0:00 5:44

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of Translational and Clinical?

This episode is 5 minutes long.

When was this Translational and Clinical episode published?

This episode was published on December 10, 2014.

Can I download this Translational and Clinical episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.